Spyre Therapeutics Inc. stocks have been trading up by 13.54 percent after upbeat clinical progress headlines boosted investor optimism.
Click Here for a Millionaire's POV on Trading SYRE
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Part A of Spyre Therapeutics’ Phase 2 SKYLINE trial in ulcerative colitis met the primary endpoint for SPY002, with strong remission and endoscopic improvement plus class-consistent safety.
- Deutsche Bank lifted its price target on Spyre Therapeutics to $115, citing expanded opportunity after competitor Abivax reported a malignancy safety signal in Phase 3 ulcerative colitis.
- Wedbush raised its Spyre Therapeutics price target to $100, calling SPY002’s first efficacy data class-consistent with no new safety signals in induction therapy.
- BTIG boosted its Spyre Therapeutics target to $112 and increased modeled success odds across TL1A assets in ulcerative colitis, Crohn’s disease, and rheumatoid arthritis.
- Enrollment is complete in Spyre Therapeutics’ SKYWAY Phase 2 basket trial of SPY072 in rheumatic diseases, locking in multiple 2026 data catalysts.
Live Update At 16:01:50 EDT: On Monday, June 22, 2026 Spyre Therapeutics Inc. stock [NASDAQ: SYRE] is trending up by 13.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
For active traders, SYRE is trading like a biotech name with real momentum behind it. Over the last few weeks, Spyre Therapeutics has pushed from the low-$70s to roughly $100, with the latest close at $100.32. That is a sharp uptrend, and the daily chart shows higher lows stacking from late May into late June, which is what momentum traders want to see.
Intraday, SYRE’s 5‑minute tape shows tight action around $100 for most of the afternoon, with repeated holds above $99.50 and quick bounces on dips. That kind of steady grind, not wild spikes, often signals strong hands building positions rather than pure day-trading churn.
More Breaking News
- KEEL Stock Climbs As Traders Focus On Cash And Volatility
- AMBQ Stock Grinds Higher As Bulls Defend Key Levels
- BTQ Stock Slides As Momentum Traders Watch Key Support
- RKT Stock Slips As Downgrade Collides With Weak Housing Data
Fundamentally, Spyre Therapeutics is still a classic development-stage biotech: deep in the red, but well capitalized. Q1 2026 showed a net loss of about $69M and negative operating cash flow near $57M, with free cash flow also around -$57M. Returns on equity and assets are strongly negative, reflecting heavy R&D spend and no commercial revenue yet. But SYRE ended the quarter with about $97M in cash and roughly $741M including short-term investments, plus a current ratio near 9 and essentially no debt. That balance sheet gives Spyre Therapeutics room to keep funding trials, which matters for traders betting on clinical catalysts rather than near-term profitability.
Why Traders Are Watching SYRE Right Now
The core driver behind SYRE’s recent move is simple: data and upgrades. Spyre Therapeutics reported that Part A of its Phase 2 SKYLINE trial in ulcerative colitis hit the primary endpoint for SPY002. The study showed statistically significant improvement on the RHI score, along with high clinical remission and endoscopic improvement rates. Just as important, the safety profile lined up with the TL1A class, with no new red flags. In biotech trading, that combination — efficacy plus clean, expected safety — is exactly what re-rates a story.
Wall Street reacted fast. Wedbush raised its price target on Spyre Therapeutics to $100 from $80 after those first efficacy results, reiterating an Outperform rating and underscoring that the data look competitive versus other TL1A drugs. BTIG followed by lifting its target from $98 to $112, explicitly increasing its modeled probabilities of success not only for SPY002 in ulcerative colitis, but also for TL1A assets in Crohn’s disease and rheumatoid arthritis. When analysts start lowering discount rates in their models, they are effectively saying the risk profile of the story has changed.
Deutsche Bank pushed its Spyre Therapeutics target even higher, from $102 to $115, after rival Abivax reported a malignancy safety signal in a Phase 3 ulcerative colitis trial. For traders, that’s a double tailwind: positive SPY002 data and a key competitor stumbling on safety. It shifts the perceived opportunity in the ulcerative colitis market more toward SYRE.
Beyond SPY002, Spyre Therapeutics has fully enrolled all sub-studies in its SKYWAY Phase 2 basket trial of SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. That sets up multiple readouts in 2026, keeping a steady catalyst calendar. SYRE is also hitting the conference circuit, with presentations lined up at major healthcare events, which often helps fuel institutional interest and trading volume.
Conclusion
For traders, SYRE is shaping up as a textbook biotech momentum play driven by data, not hype. Spyre Therapeutics has validated its TL1A strategy in ulcerative colitis with SPY002, cleared a key safety overhang, and now sits in a stronger competitive spot after Abivax’s Phase 3 safety issue. The stock’s move from the low-$70s into the $100 area tracks directly with that narrative and with a wave of price target hikes from Wedbush, BTIG, and Deutsche Bank.
At the same time, the numbers remind everyone what this story really is: a high‑burn, pre‑revenue biotech with heavy R&D and negative earnings. Spyre Therapeutics’ strong cash and investment position and minimal debt buy it time, but the whole thesis still hangs on clinical execution. SPY072’s Phase 2 basket trial and the multiple 2026 readouts matter a lot — they are the next big checkpoints that can extend or break the current momentum.
Traders in the Tim Sykes community focus on exactly these setups — clear catalysts, liquid charts, and the discipline to treat every trade as a trade, not a marriage. That discipline is echoed across the trading education world; as Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only the price action and the catalysts.” For SYRE, those catalysts are front and center right now, and price action is confirming that the crowd is paying attention. This article is for educational and research purposes only and should not be taken as investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.